AU2022365519A1 - Compositions and methods for drug instillation into the urinary bladder - Google Patents

Compositions and methods for drug instillation into the urinary bladder Download PDF

Info

Publication number
AU2022365519A1
AU2022365519A1 AU2022365519A AU2022365519A AU2022365519A1 AU 2022365519 A1 AU2022365519 A1 AU 2022365519A1 AU 2022365519 A AU2022365519 A AU 2022365519A AU 2022365519 A AU2022365519 A AU 2022365519A AU 2022365519 A1 AU2022365519 A1 AU 2022365519A1
Authority
AU
Australia
Prior art keywords
phase
composition
bladder
active agent
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022365519A
Other languages
English (en)
Inventor
Avigdor GORDON
Nadav Malchi
Taher Nasser
Dan Touitou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigone Pharma Ltd
Original Assignee
Trigone Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigone Pharma Ltd filed Critical Trigone Pharma Ltd
Publication of AU2022365519A1 publication Critical patent/AU2022365519A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022365519A 2021-10-17 2022-10-14 Compositions and methods for drug instillation into the urinary bladder Pending AU2022365519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256583P 2021-10-17 2021-10-17
US63/256,583 2021-10-17
PCT/IL2022/051090 WO2023062638A1 (en) 2021-10-17 2022-10-14 Compositions and methods for drug instillation into the urinary bladder

Publications (1)

Publication Number Publication Date
AU2022365519A1 true AU2022365519A1 (en) 2024-05-02

Family

ID=85987609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022365519A Pending AU2022365519A1 (en) 2021-10-17 2022-10-14 Compositions and methods for drug instillation into the urinary bladder

Country Status (8)

Country Link
US (1) US20250228767A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415821A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539581A (cg-RX-API-DMAC7.html)
KR (1) KR20240089461A (cg-RX-API-DMAC7.html)
CN (1) CN118234483A (cg-RX-API-DMAC7.html)
AU (1) AU2022365519A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235477A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023062638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180652A1 (en) * 2024-02-28 2025-09-04 Farco-Pharma Gmbh Drug delivery systems for instillation in the urinary bladder comprising active pharmaceutical ingredients

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
JPH08157370A (ja) * 1994-12-06 1996-06-18 Banyu Pharmaceut Co Ltd フィナステリド含有徐放性組成物
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
FR2756493B1 (fr) * 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
AU6876498A (en) * 1997-04-03 1998-10-22 Point Biomedical Corporation Intravesical drug delivery system
HK1049443A1 (zh) * 1999-11-12 2003-05-16 Angiotech Pharmaceuticals, Inc. 用放射活性疗法和细胞循环抑制剂联合治疗疾病的组合物和方法
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US9248219B2 (en) * 2007-09-14 2016-02-02 Boston Scientific Scimed, Inc. Medical devices having bioerodable layers for the release of therapeutic agents
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
DE212011100034U1 (de) * 2010-01-20 2012-07-04 Theracoat Ltd. Material zur Behandlung von inneren Hohlräumen
US8754564B2 (en) * 2010-05-27 2014-06-17 Covidien Lp Hydrogel implants with varying degrees of crosslinking
US9757497B2 (en) * 2011-05-20 2017-09-12 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
WO2013011504A1 (en) * 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
DK2836200T3 (da) * 2012-04-08 2020-09-21 Urogen Pharma Ltd Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
US9801854B1 (en) * 2014-01-17 2017-10-31 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
WO2018055550A1 (en) * 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
WO2018227293A1 (en) * 2017-06-13 2018-12-20 The University Of British Columbia Polymeric paste compositions for drug delivery
EP3962449A1 (en) * 2019-04-30 2022-03-09 Trigone Pharma Ltd Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
CA3167259A1 (en) * 2020-02-07 2021-08-12 Veronika SCHMITT Mucoadhesive polymeric drug delivery compositions and methods

Also Published As

Publication number Publication date
JP2024539581A (ja) 2024-10-29
KR20240089461A (ko) 2024-06-20
EP4415821A1 (en) 2024-08-21
WO2023062638A1 (en) 2023-04-20
CN118234483A (zh) 2024-06-21
CA3235477A1 (en) 2023-04-20
EP4415821A4 (en) 2025-02-26
US20250228767A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
CN109528695B (zh) 一种治疗类风湿性关节炎的微针透皮给药贴片及其制备方法
US20220118096A1 (en) Material and method for treating internal cavities
JP5986149B2 (ja) 女性の尿失禁を治療するための用具および方法
AU2020265812B2 (en) Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
US20090148498A1 (en) Controlled release implantable dispensing device and method
CN114177133B (zh) 一种药物缓释载体、缓释药物组合物及其应用
US12171747B2 (en) Material and method for treating cancer
US10039709B2 (en) Bioadhesive compositions for epithelial drug delivery
EA030133B1 (ru) Фармацевтический препарат контролируемого высвобождения, содержащий гликозаминогликан, для лечения заболеваний кишечника
US20250228767A1 (en) Compositions and methods for drug instillation into the urinary bladder
US20070172507A1 (en) Transluminal drug delivery methods and devices
JP6250005B2 (ja) 制御放出製剤
CN114796122B (zh) 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
Zhu et al. Addition of Ostrea rivularis polysaccharides in microneedle loaded with 3-acetylaconitine liposomes enhance analgesic activities and drug delivery properties
US20250275988A1 (en) Formulation for treating urinary system disorders
KR101010411B1 (ko) 온단세트론의 직장내 투여를 위한 온도 감응성 액상좌제조성물
JP2024539581A5 (cg-RX-API-DMAC7.html)
CN116492313A (zh) 一种口服雷公藤红素纳米制剂及其制备方法与应用
WO2025180652A1 (en) Drug delivery systems for instillation in the urinary bladder comprising active pharmaceutical ingredients
WO2019172920A1 (en) Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain
CN1287798C (zh) 长效孕激素注射埋植剂制备方法和应用
Jost Treatment of anal fissure with botulinum toxin-A